Alzinova AB (ALZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alzinova AB (ALZ) has a cash flow conversion efficiency ratio of -0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-16.80 Million ≈ $-1.81 Million USD) by net assets (Skr148.71 Million ≈ $16.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alzinova AB stock valuation for the company's overall valuation and market capitalisation.
Alzinova AB - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Alzinova AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alzinova AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alzinova AB ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Alzinova AB to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LBI Capital Bhd
KLSE:8494
|
-0.200x |
|
Moonpig Group PLC
LSE:MOON
|
-0.276x |
|
Palamina Corp
V:PA
|
-1.095x |
|
Wise Group AB
ST:WISE
|
0.075x |
|
Green Packet Bhd
KLSE:0082
|
0.221x |
|
Reliance Chemotex Industries Limited
NSE:RELCHEMQ
|
0.161x |
|
Nexted Group Ltd
AU:NXD
|
0.510x |
|
TFP Solutions Bhd
KLSE:0145
|
-0.142x |
Annual Cash Flow Conversion Efficiency for Alzinova AB (2014–2025)
The table below shows the annual cash flow conversion efficiency of Alzinova AB from 2014 to 2025. View ALZ stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr121.96 Million ≈ $13.12 Million |
Skr-13.03 Million ≈ $-1.40 Million |
-0.107x | +34.72% |
| 2024-12-31 | Skr123.82 Million ≈ $13.33 Million |
Skr-20.27 Million ≈ $-2.18 Million |
-0.164x | -22.49% |
| 2023-12-31 | Skr113.86 Million ≈ $12.25 Million |
Skr-15.21 Million ≈ $-1.64 Million |
-0.134x | -36.72% |
| 2022-12-31 | Skr105.53 Million ≈ $11.36 Million |
Skr-10.31 Million ≈ $-1.11 Million |
-0.098x | +11.95% |
| 2021-12-31 | Skr88.47 Million ≈ $9.52 Million |
Skr-9.82 Million ≈ $-1.06 Million |
-0.111x | -70.10% |
| 2020-12-31 | Skr96.02 Million ≈ $10.33 Million |
Skr-6.27 Million ≈ $-674.29K |
-0.065x | +2.98% |
| 2019-12-31 | Skr59.11 Million ≈ $6.36 Million |
Skr-3.98 Million ≈ $-427.85K |
-0.067x | -8.08% |
| 2018-12-31 | Skr63.75 Million ≈ $6.86 Million |
Skr-3.97 Million ≈ $-426.95K |
-0.062x | +14.16% |
| 2017-12-31 | Skr29.39 Million ≈ $3.16 Million |
Skr-2.13 Million ≈ $-229.31K |
-0.072x | +16.33% |
| 2016-12-31 | Skr31.90 Million ≈ $3.43 Million |
Skr-2.76 Million ≈ $-297.46K |
-0.087x | +44.29% |
| 2015-12-31 | Skr20.63 Million ≈ $2.22 Million |
Skr-3.21 Million ≈ $-345.40K |
-0.156x | +66.23% |
| 2014-12-31 | Skr1.55 Million ≈ $167.09K |
Skr-715.19K ≈ $-76.97K |
-0.461x | -- |
About Alzinova AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide … Read more